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Abstract
Critical to the design and assessment of interventions for enteropathy and its developmen-
tal consequences in children living in impoverished conditions are non-invasive biomarkers
that can detect intestinal damage and predict its effects on growth and development. We
therefore assessed fecal, urinary and systemic biomarkers of enteropathy and growth pre-
dictors in 375 6–26 month-old children with varying degrees of malnutrition (stunting or
wasting) in Northeast Brazil. 301 of these children returned for followup anthropometry
after 2-6m. Biomarkers that correlated with stunting included plasma IgA anti-LPS and anti-
FliC, zonulin (if >12m old), and intestinal FABP (I-FABP, suggesting prior barrier disrup-
tion); and with citrulline, tryptophan and with lower serum amyloid A (SAA) (suggesting
impaired defenses). In contrast, subsequent growth was predicted in those with higher
fecal MPO or A1AT and also by higher L/M, plasma LPS, I-FABP and SAA (showing intesti-
nal barrier disruption and inflammation). Better growth was predicted in girls with higher
plasma citrulline and in boys with higher plasma tryptophan. Interactions were also seen
with fecal MPO and neopterin in predicting subsequent growth impairment.
Biomarkers clustered into markers of 1) functional intestinal barrier disruption and trans-
location, 2) structural intestinal barrier disruption and inflammation and 3) systemic inflam-
mation. Principle components pathway analyses also showed that L/M with %L, I-FABP
and MPO associate with impaired growth, while also (like MPO) associating with a systemic
inflammation cluster of kynurenine, LBP, sCD14, SAA and K/T. Systemic evidence of LPS
PLOS ONE | DOI:10.1371/journal.pone.0158772 September 30, 2016 1 / 20
a11111
OPENACCESS
Citation: Guerrant RL, Leite AM, Pinkerton R,
Medeiros PHQS, Cavalcante PA, DeBoer M, et al.
(2016) Biomarkers of Environmental Enteropathy,
Inflammation, Stunting, and Impaired Growth in
Children in Northeast Brazil. PLoS ONE 11(9):
e0158772. doi:10.1371/journal.pone.0158772
Editor: Christopher R. Weber, University of
Chicago Medical Center, UNITED STATES
Received: April 14, 2016
Accepted: June 21, 2016
Published: September 30, 2016
Copyright: © 2016 Guerrant et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files. Individual participant data are not publicly
available due to ethical restrictions. Requests for
further data can be sent to rlg9a@virginia.edu.
Funding: This work was supported by the Bill &
Melinda Gates Foundation Biomarker Grants No.
OPP1066140 entitled, "Novel metabonomic
biomarkers of gut function and health: Modeling
enteropathy (EE) and field validation,” and in part
by OPP 1066146 and OPP 1099111 “Production of
a Reg1B fecal enzyme immunoassay as a potential
translocation associated with stunting, while markers of barrier disruption or repair (A1AT
and Reg1 with low zonulin) associated with fecal MPO and neopterin.
We conclude that key noninvasive biomarkers of intestinal barrier disruption, LPS trans-
location and of intestinal and systemic inflammation can help elucidate how we recognize,
understand, and assess effective interventions for enteropathy and its growth and develop-
mental consequences in children in impoverished settings.
Introduction
Children living in impoverished areas around the world often develop stunted growth from 4
to 24 months of age, a concern that is heightened by potential lasting consequences of impaired
cognitive development [1–5]. Increasingly sensitive detectionmethods are revealing that multi-
ple and repeated intestinal infections are evenmore common (with and without overt diarrheal
illnesses) in young children living in impoverished areas lacking in adequate sanitation or
clean water [6, 7]. These heavy pathogen burdens may associate with growth faltering or cogni-
tive impairment [8–14]. Undernutrition is also common and may further worsen the impact of
enteric infections on growth and development, leading to a potential “vicious cycle” of malnu-
trition and enteric infections [15–17]. These potential relationships can be causally dissected in
animal models, where certain enteric infections, such as Cryptosporidium or enteroaggregative
Escherichia coli [18, 19] or even certainmixed Bacteroidetes and Proteobacteria [20] can fur-
ther worsen the growth impairment and intestinal damage in undernourished states. In the lat-
ter case, a malnourishing diet resulted in growth failure and microbiome alterations, but
without intestinal damage unless certainmixed microbiota were added. This problem of envi-
ronmental enteropathogens inducing enteric dysfunction has been recognized for over half a
century in tropical, developing areas and among Peace Corps volunteers [15, 21, 22]. More
recently this clinical entity has been associated with the concept of disruption of gut barrier
function, passage of microorganisms and/or their bioproducts from the intestinal lumen to the
lamina propria, and mucosal inflammation, ultimately leading to damage of villous architec-
ture and further impaired digestive and absorptive functions and barrier disruption, thereby
generating a vicious cycle of impaired gut functions referred to as “Environmental Enteropa-
thy” (EE) [23]. Numerous extensive studies have suggested that different assessments of intesti-
nal barrier disruption, local and systemic inflammatory responses can associate with not only
impaired growth, but also with poor household environments that likely predispose to enteric
infections and EE [24–29]. Yet this hugely important problem for healthy child growth and
development remains poorly understood [30]. Our objective therefore was to examine a wide
range of potential fecal, urinary and plasma biomarkers to determine how they associate with
each other and with malnutrition (defined by height or weight for age) and to determine which
ones best predict impaired subsequent growth.
The need is great for biomarkers that can predict both EE onset and its longer term growth
and developmental impact as well as to evaluate potential interventions designed to ameliorate
these mechanisms and improve clinical outcome. We therefore examined potential biomarkers
that might associate functional and structural “enteropathy” with malnutrition or with subse-
quent growth impairment in children enrolled in a study of malnutrition at a nutrition clinic
serving several impoverished communities in and near Fortaleza, Ceará in Northeast Brazil. In
particular, we assessed potential plasma, urine and fecal biomarkers of intestinal epithelial or
barrier disruption, evidence of bacterial product translocation and intestinal and systemic
inflammatory responses, and intestinal permeability.
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Methods
Study location and population
The study was conducted at Promotion of Nutrition and Human Development (IPREDE)
clinic located in Fortaleza, CE, Brazil. Details of the geographic location, population, demo-
graphics, environmental and socioeconomic status have been described elsewhere [31]; this
outpatient clinic serves children from several impoverished communities in and near Fortaleza,
often with moderate or severe malnutrition, having weight-for-age z-scores and height-for-age
z-scores (WAZ or HAZ) ranging from -2 to -6. Standard nutrition education and supplementa-
tion was provided according to local standards based onWorld Health Organization guidelines
[32]. The study started in Aug, 2010 and ended with follow up in Sep, 2013. Malnourished or
“case” children were initially defined as having WAZ scores<-2 and, to the extent possible,
age and gender matched ‘non-malnourished controls’ were defined as having a WAZ better
than -1. However, others have correlated linear growth (or HAZ) with EE or other outcomes
such as cognitive impairment [3]; hence we have examined bothWAZ and HAZ in these anal-
yses. Children were excluded if they had underlying recognizeddisease (other than malnutri-
tion) or if they did not have a responsible parent or guardian16 years old. After obtaining
informed consent from the responsible parent or guardian, a total of 402 children aged 6–26
months (201 malnourished and 201 age and gender-matched non-malnourished)were
enrolled betweenAugust 30, 2010 and July 12, 2013; 375 provided fecal and blood samples and
completed a lactulose-mannitol absorption test, and were asked to return for followup in 2–6
months.
The MAL-ED case-control study protocol and consent forms were approved by the local
institutional review board (IRB) at Universidade Federal do Ceará, the national IRB, Conselho
Nacional de Ética em Pesquisa, Brasília, DF, Brazil, and the IRB at the University of Virginia,
VA. The consent forms were reviewed and signed by the responsible parents or caregivers at
the time of the screening process of the study protocol.
Anthropometry and biomarker assessments and statistical analyses
Detailedmethods for anthropometric measurements, assessment of blood, stool, and urine bio-
markers and statistical methods are provided in S1 File. As shown in Table 1, 375 children
were enrolled and had initial anthropometry and were invited to provide a fecal specimen,
have a L/M absorption test and to have blood obtained for testing potential biomarkers of
Table 1. Demographic information for study participants (Children and caregivers; n = 375 at study
start, except where otherwise noted).
Child
Gender (n, % male) 180/375 (48%)
Age Months (mean ± SD) 14.3 ± 5.4 (n = 375)
Birth WAZ (mean ± SD) (by caregiver’s report) -1.07 ± 1.7 (n = 365)
Breastfeeding (n, %Yes) 210/375 (56%)
Diarrhea on Day of Visit (n, %Yes) 10/375 (2.7%)
Caregiver (n = 375)*
Age Years (mean ± SD) 26.3 ± 6.5 n = 373
Years Education 7.9 ± 3.0 n = 373
Age of 1st Pregnancy 18.6 ± 4.2 n = 373
*Mother, n = 337;Grandmother, n = 27; Father, n = 9; other, n = 2.
doi:10.1371/journal.pone.0158772.t001
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intestinal barrier function, intestinal and systemic inflammation and injury repair. Shown in
Table 2 are the 13 plasma, 4 fecal and urinary tests with at least 274 valid results obtained from
within 1 month of enrollment. Markers of barrier function included urinary L/M absorption,
fecal A1AT, Reg-1, and plasma LPS (acute levels, by neutralization luminescence [LUM]
assay), IgG and IgA anti-LPS anti-FliC, zonulin, I-FABP and, with limited amounts of plasma
available, claudin-15. Fecal MPO and neopterin were tested to assess intestinal inflammation,
and plasma SAA, sCD14, LBP, citrulline, tryptophan and kynurenine were measured to assess
systemic inflammatory responses and as potential predictors of intestinal injury repair. These
18 markers of intestinal barrier disruption and inflammation had adequate samples for assay
in at least 274 (to 321) children at enrollment for study of associations with enrollment stunt-
ing (or wasting). Of several fecal biomarkers that have been used to assess intestinal inflamma-
tion, we selectedmyeloperoxidase (MPO) as our main test fecal marker of acute neutrophilic
intestinal inflammation because of its ready availability, relatively less influence by age or
breast-feeding and its potential use in murine models of enteropathy. In a separate analysis
comparing fecal MPO, lactoferrin, calprotectin and lipocalin-2, we found that they correlate
well with each other [33].
In addition, followup anthropometry at 2–6 months after initial sampling enabled us to
assess these biomarkers as predictors of subsequent growth.We also assessed their associations
with each other as well as with separately studied comparisons of fecal lactoferrin, calprotectin
and lipocalin, and plasma hsCRP, and claudin-15. RepeatedMeasures MANOVA analyses
were used to model mean growth from Study Start to follow-up anthropometric measurement
obtained within 2 to 6 months later by children with low and high levels of each biomarker
while controlling for child age and gender. Interaction effects of gender with biomarker were
also assessed for each model. Similarly interaction effects of study start growth status (stunting
present or not) of biomarkers on growth were assessed, although these results were not
significant.
Table 2. Frequencies of biomarker testing, including 13 tests on plasma, 4 on fecal and L/M absorp-
tion testing on urine as shown. *Of 326 children with samples obtained within 1 month of study start.
Plasma Biomarkers # with Valid results*
SAA 281
LBP 281
sCD14 277
I-FABP 281
kyn 283
try 283
AdjFlicIgA 292
AdjLPSIgG 292
AdjFlicIgG 292
AdjLPSIgA 292
citrulline 283
LPS_Nutri_Enz (LUM) 289
Zonulin 288
Fecal and Urine (L/M) Biomarkers
MPO 321
REG1 315
A1AT 289
Neo 234
L/M (and %L and %M) 274
doi:10.1371/journal.pone.0158772.t002
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Missing data analysis (Pearson correlations between known characteristics of participants
retained or failed to return for followup or were missing biomarker results because of sample
limitations) showed that children with caregivers having fewer years of education were missing
more of three biomarkers (A1AT, Reg1,MPO, r -0.18) compared to their more educated
counterparts. Boys were disproportionately missing A1AT results (r = 0.15 p = 0.003), older
children were more likely to be missing Neopterin (r = 0.12 p = 0.017) while nonbreastfeeding
(r = -0.10, p = 0.37) and more wasted children (r = -0.12, p = 0.026) are missing more L/Ms. To
account for bias in followup, multiple regression was used to impute missing data for all bio-
markers with at least 274 (73% of 375) complete data. Principle Components Analyses (PCA)
were then used to combine related combinations of 11 barrier function, 2 intestinal inflamma-
tion and then 7 systemic biomarkers. These related sets of biomarkers were then correlated
among each other as well as to children’s growth status and growth trajectory initially using
Partial Pearson correlations and ultimately using Multiple Regression. All analyses predicting
anthropometric status and growth trajectories included controlling for child age and gender.
Results
Markers of malnutrition (individual biomarkers at enrollment study start,
ss)
Several plasma biomarkers suggesting prior intestinal barrier disruption were significantly cor-
related with stunting or wasting, as assessed by HAZ or WAZ at study start, respectively, in
children when they were first enrolled (ie at study start, ss). As shown in Fig 1 (and in S1
Table), these included plasma IgA anti-LPS antibody, zonulin (in all children for WAZ and, for
HAZ in children>12 months old), and I-FABP. IgA anti-flagellin and anti-LPS antibodies
(n = 292; r = 0.15, p = 0.011 and r = 0.14, p = 0.017) as well as intestinal fatty acid binding pro-
tein (I-FABP; n = 281; r = 0.14; p = 0.024) associate with worse stunting (i.e. lower HAZ SS
scores) at the time of enrollment, suggesting greater prior exposure to LPS and release of an
intestinal cytosolic protein, thus enterocyte damage, respectively. In addition, citrulline (as a
marker of intestinal injury repair) and lower SAA (suggesting impaired defenses) correlated
with stunting at enrollment.
Predictors of subsequent growth (individual biomarkers with delta HAZ)
Several biomarkers of intestinal inflammation and barrier disruption (or “environmental enter-
opathy”) at the time of sampling were predictive of subsequent growth. Of importance, subse-
quent growth was significantly worse in those with higher fecal MPO or A1AT (Fig 2A and
2B), and growth impairment correlated with higher L/M, LPS, I-FABP and SAA (Fig 1 and Fig
2C–2F) in showing fecal and systemic markers of intestinal inflammation and barrier disrup-
tion or enteropathy).
Claudin-15 (Cdn-15), even with relatively few (n = 35–42) matching samples, significantly
correlates with lower L/M, A1AT, Reg-1 and lipocalin-2, all markers (when lower) of 'better'
mucosal integrity/barrier function, and all consistent with the previously recognized associa-
tions of Cdn-15 with healthy absorptive surface function and barrier function in animal models
[34] (see S2 Table).
Citrulliine predicts growth in girls and tryptophan in boys
Shown in Fig 3 (Fig 3A and 3B) are the associations of plasma citrulline (esp. in girls) and tryp-
tophan (in boys) with improved growth. The linear association of plasma citrulline levels with
weight gain is significant for all 246 children (r = 0.15, p = 0.018). Bivariate analyses show this
Biomarkers of Enteropathy, Stunting and Growth
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is predominantly accounted for by improved growth among the 131 girls (p<0.001). Con-
versely, the association of plasma tryptophan with better subsequent growth was only seen in
the 114 boys (p = 0.010). Furthermore, higher kynurenine/tryptophan ratios correlate with
fecal MPO and systemic hsCRP (and negatively with citrulline) (S1 Table).
Interaction of MPO and neopterin
As shown in Fig 4 (Fig 4), RepeatedMeasures MANOVAs also shows an interaction effect in
predicting growth: highMPO when combined with high neopterin associates with poorest
growth. Thus, MPO combines with neopterin to show subsequent growth impairment; how-
ever, neopterin may also, in the absence of intestinal inflammation (ie low MPO), reflect
“healthier” host cellular immune responses and thus correlate with better growth (again show-
ing a significant interaction of MPO with neopterin).
Clustering of biomarkers with each other
The biomarkers tested tend to cluster as markers of intestinal barrier function (including LPS
translocation), intestinal inflammation, or systemic inflammation as shown in Fig 5 (Fig 5) and
in S2 Table. Specifically, in Fig 5 a cluster dendrogramwith Pearson correlations among those
biomarkers with274 values are three main groups: the first representing the translocation
markers, LPS and IgA and IgG anti-LPS or FliC as well as zonulin and the 2 predictors of sub-
sequent growth, tryptophan and citrulline. The second group shows predominantly systemic
responses to disrupted barrier function and translocation, while the third group are the mark-
ers of specific intestinal barrier disruption or local intestinal inflammation. Thus groups 1 and
Fig 1. Heat map showing all significant partial Pearson correlations of barrier and systemic biomarkers
with HAZ or WAZ at enrollment (ie. study start, ss) or with changes in (Δ) HAZ or WAZ. Significant
correlations (at p<0.05; * = p<0.01) between biomarkers and growth, controlling for child age and gender.
HAZ = height for age Z score; WAZ = weight for age z score; ss = study start; Δ = change in HAZ or WAZ at 2-6m
followup; numbers range from 230 to 292 except for zonulin at age >12m where n = 172. Full r, p and df values are
provided in S1 Table.
doi:10.1371/journal.pone.0158772.g001
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3 likely lead to the group 2 systemic responses in associating with each other as well as fitting
our concept of the pathogenesis of enteropathy. Shown in Fig 5 for the274 biomarkers avail-
able within 1 month of enrollment and, more extensively for all tests done in S2 Table, fecal
MPO correlates with fecal A1AT, and Reg-1, as well as with urinary L/M ratios, % lactulose
and even with kynurenine, K/T ratios and (negatively) with tryptophan. Fecal MPO also corre-
lated significantly with neopterin, albeit in smaller numbers available for neopterin at study
start (n = 233; but with n = 279, r = 0.238, p<0.001 for all samples tested shown in S2 Table).
Published separately using a subset of 77 of these fecal samples for comparative simultaneous
studies of fecal MPO, lactoferrin (LF), calprotectin (FC) and Lipocalin-2 (Lcn-2) [33], we
found that the neutrophil markers, MPO, LF and FC correlated best, but also, albeit less tightly,
with Lcn-2. The full sample shows that fecal Reg-1 also correlated with A1AT and the intestinal
Fig 2. Fecal MPO, Fecal alpha-1-antitrypsin (A1AT), and plasma LPS, FABP and SAA each predicts subsequent growth impairment. a: For MPO,
p = 0.028; n = 266 when correcting for age and gender, and independent of breastfeeding status (that showed no correlation in these 6-26m old children)
and of age. b: For A1AT, n = 237; p = 0.042; and A1AT also correlates with “catchup WAZ” as well, p = 0.035 after correcting for age and gender. c: For
urine L/M, higher values correlated (controlling for age and gender) with impaired growth (delta HAZ) (r = -0.173; p = 0.009; n = 230). d: For plasma LPS (ie
lower LUM), higher values correlated with impaired growth (delta HAZ) (r = 0.151; p = 0.017; n = 251). e: For plasma FABP, higher values correlated with
impaired growth (delta HAZ) (r = -0.134; p = 0.042; n = 231). f: For plasma SAA, higher values correlated with impaired growth (delta HAZ) (r = -0.132;
p = 0.046; n = 231).
doi:10.1371/journal.pone.0158772.g002
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epithelial biomarker Lcn-2 as well as with the inflammation biomarkers, lactoferrin,MPO or
neopterin (Fig 1). In addition, fecal MPO correlates with several plasma biomarkers suggesting
systemic inflammatory responses, including hsCRP (again, in S2 Table, with smaller numbers,
but still significant at p<0.005; r = 0.238; n = 142), as well as with SAA, kynurenine, K/T and
negatively with tryptophan.
Pathway model, using clusters of biomarkers to predict malnutrition and
growth
Shown in Fig 6 (Fig 6) are the results of principle components factor analyses to assess parsi-
monious linear pathways of grouped biomarkers as they relate to children’s growth status and
subsequent growth. Available biomarker data with sufficient numbers for this principle com-
ponent analysis that can be considered to reflect disruption of intestinal barrier function fall
into 3 groups as shown, reflecting (B1) LPS ‘translocation’, (B2) absorptive function and epi-
thelial cell damage (L/M and I-FABP), and (B3) further barrier disruption (ex Reg1 and A1AT)
with tight junctionmodulation (zonulin). Most importantly, these factor analyses reveal
Fig 3. Plasma citrulline (in girls) and tryptophan (in boys) predicts subsequent better growth. A. citrulline (for which gender differs
significantly) in girls (p<0.001; n = 131; median citrulline = 23.97 umol/L) and B. tryptophan in boys (p = 0.010; n = 114; median
tryptophan = 66umol/L) predicts subsequent better growth.
doi:10.1371/journal.pone.0158772.g003
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associations of two pathways that associate with impaired subsequent growth: B2 (disrupted
absorptive function and epithelial damage) and MPO (indicating intestinal inflammation); B2
additionally associates with MPO.
In addition, group B1 (markers of past and recent LPS translocation) associates with stunt-
ing at the time of enrollment (‘study start,’ or HAZss); and B2 barrier/absorptivedisruption
with the systemic cluster (S1: Kyn, K/T, LBP, sCD14, and SAA). Like B2 (barrier/absorptive
disruption), the other cluster showing barrier disruption, B3, also associates separately with
MPO, and with neopterin. Finally, stunting at enrollment highly significantly predicted ‘catch-
up’ growth (ie stunted children indeed did show greater growth that has been termed ‘catch-
up’ growth).
Multiple Linear Regression analysis showed HAZss (p<0.001), MPO (p = 0.041) and B2
(p = 0.021) are significant independent predictors of subsequent growth impairment (delta
HAZ), after controlling for child age and gender (R2 = .11, p<0.001), or 11% of the growth
impairment seen in these children.
Discussion
The need for simple, sensitive biomarkers of environmental enteropathy (EE) in readily avail-
able fecal, blood or urine specimens lies in the magnitude of its impact and the need to under-
stand and develop effective interventions. One in every three children in developing areas
become stunted in their critically formative first 2 years of life, likely related at least in part to
increased exposure to environmental pathogens, often as they are weaned in settings of inade-
quate water and sanitation [35–37]. The potential developmental consequences of enteropathy
with or without overt diarrhea or stunting can be devastating to the full physical and neurocog-
nitive development in one third of the world’s children growing up in impoverished areas.
Thus early recognition and intervention in those at greatest risk is of paramount importance.
Our findings focus attention on intestinal barrier and absorptive function and inflammation
Fig 4. Repeated measures MANOVAs show interactions in predicting growth between MPO and Neo: high MPO when combined
with high neopterin associate with poorest growth.
doi:10.1371/journal.pone.0158772.g004
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that might reflect increased functional gut permeability (assessed by L/M permeability testing
and by serum zonulin levels) and on translocation of microbial products like LPS which then
Fig 5. Cluster dendrogram with Pearson correlations among those biomarkers with274 values showing three main groups: 1)
translocation markers, LPS and IgA and IgG anti-LPS or FliC as well as zonulin and the 2 potential predictors of subsequent
growth, tryptophan and citrulline; 2) predominantly systemic responses to disrupted barrier function and translocation; and 3)
markers of specific intestinal barrier disruption or local intestinal inflammation. As discussed, groups 1 and 3 may predispose to group
2 systemic responses in associating with each other as shown in the heat map as would fit our concept of the pathogenesis of enteropathy.
doi:10.1371/journal.pone.0158772.g005
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may trigger local and systemic inflammatory responses leading to further structural
impairment of gut barrier (A1AT) and, ultimately, stunting growth that characterize EE.
With respect to biomarkers that associate with already stunted children, we find increased
systemic IgA antibody against the microbial markers, LPS or FliC (suggesting prior transloca-
tion of microbial products), as well as Intestinal-FABP (a marker of enterocyte death) and, in
children over 12 months of age, plasma zonulin all suggesting prior intestinal barrier disrup-
tion. Similarly, the negative association of the LPS ‘cluster’ (B1) with HAZss is seen in the Prin-
ciple Components (Partial Pearson correlation) analyses shown in Fig 6. Conversely, the
association of reduced SAA in stunted children may reflect an impairment in their host defense
responses. In addition, greater citrulline and tryptophan levels in stunted children suggest their
involvement in the needed intestinal injury repair or ‘catch-up’ growth, that is clearly greater
in these stunted children.
In contrast, biomarkers that help ‘predict’ subsequent growth show the importance of an
initial disruption of the intestinal barrier, translocation of LPS and local intestinal and
Fig 6. Path model, using Principle Components Analyses (Equamax rotation solution maximizing independence of groups) showing
associations among 1) Barrier (green), 2) Local Gut (orange) and 3) Systemic (pink) sets of biomarkers, as well as their predictive utility
regarding linear growth.
doi:10.1371/journal.pone.0158772.g006
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inflammatory signaling as well as the importance of key building blocks like citrulline and tryp-
tophan (albeit with opposite sex associations). Children with higher fecal MPO or fecal A1AT
grow less well, and L/M, LPS (reciprocal of LUM), I-FABP and SAA all correlate significantly
with impaired subsequent growth. Similarly, the interaction of the 2 fecal markers, MPO and
neopterin shows additional power to predict subsequent growth impairment.
The differential association of select biomarkers in girls versus boys likely reflect differences
in body composition and basal metabolic rates in males vs females, which are present well
before the onset of puberty [38–46]. In addition, boys in low and middle income countries
(LMICs) are at greater risk of stunting than girls—especially boys of families with the lowest
socioeconomic resources (http://bmcpediatr.biomedcentral.com/articles/10.1186/1471-2431-
7-17). Hence, just as children's growth is monitored using sex-adjusted anthropometric indices,
the power of biomarkers to predict growth must be considered in the context of sex differences
in growth. Further work to understand the biological basis of sexual dimorphisms in growth
under adverse conditions is urgently needed.
Indeed, as shown in the cluster dendrogram in Fig 5 (Fig 5), the biomarkers themselves tend
to cluster into 3 main groups, reflecting intestinal translocation, intestinal mucosal barrier dis-
ruption and inflammation, and systemic inflammatory responses that likely contribute to the
potential long-term growth, developmental and metabolic consequences that have been attrib-
uted to repeated intestinal infections and “environmental enteropathy” in early childhood [5].
Those that indicate early tight junction effects (zonulin) cluster with the indicators of past or
recent LPS translocation and even the potential “catch-up growth” markers, tryptophan and
citrulline, while those that indicate intestinal cell and structural barrier disruption (I-FABP, L/
M, %L, A1AT and Reg1) cluster with the marker of intestinal inflammation,MPO. Finally,
markers of systemic acute phase or proinflammatory responses (SAA, Kynurenine, K/T,
sCD14 and LBP) cluster to indicate the systemic responses to intestinal barrier disruption and
inflammation that we postulate effect the troubling lasting growth, developmental and meta-
bolic consequences noted above. Somewhat similar clustering of intestinal and systemic bio-
markers has also been seen in children in Bangladesh [47].
Furthermore, our multivariate pathway analyses show that barrier function, intestinal
inflammation and systemic markers are linearly associationedwith each other as well as either
previous stunting (ie HAZss at study start) or with subsequent growth (delta HAZ). As
observedwith single biomarker analyses, this more parsimonious pathway analysis elucidates
the direct association of L/M, %L and I-FABP (B2, barrier/absorptive disruption) with growth
impairment as well as its indirect association throughMPO.
The antibody as well as ‘acute’ LPS cluster was associated with stunting at the time of sam-
pling (as was seen with the IgA antibodies in the individual partial Pearson correlations shown
in Table 2; and LPS, as reciprocal LUM, was correlated with subsequent growth impairment as
well). As lower LUM values reflect high LPS-neutralizing enzyme activity and thus higher
recent systemic LPS exposure, they correlate with subsequent growth impairment (Fig 2D),
and with higher IgA or IgG anti-FliC or anti-LPS (r = 0.300, p<0.001 for IgAαFliC; r = 0.211,
p<0.001 for IgAαLPS; r = 0.199, p = 0.001 for IgGαLPS; to r = 0.146; p = 0.014 for IgGαFliC).
Thus, while IgA or IgG antibody against LPS or FliC likely reflect prior translocation of enteric
bacterial components, hence stunting at enrollment; the more current LPS exposure, reflected
by the reciprocal luminescence assay for LPS neutralizing activity correlates better with subse-
quent growth, even though it also correlates with anti-LPS and FliC antibody that had associ-
ated with pre-enrollment stunting. Therefore, this LPS-neutralizing enzyme activity assay may
provide a better predictor of subsequent growth, irrespective of past stunting. Furthermore, it
is clear that having antibody against LPS does not protect against subsequent stunting that is
associated with recent evidence of LPS exposure. Several extensive studies have assessed LPS
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using plasma IgG anti-endotoxin core antibody (EndoCAb) as well as different measures of
endotoxin and some, but not others have found impressive associations with impaired intesti-
nal barrier function and growth [25, 28, 48]. These differencesmay relate to batch or other dif-
ferences in available assays and hence are the reason we have used different assessments in this
work. Taken together, however, consistent with our findings in this study, numerous studies
suggest that different assessments of intestinal barrier disruption, and of local and systemic
inflammation can be associated with impaired growth.
The third ‘barrier’ cluster (B3) of increasedA1AT, Reg-1 and lower zonulin correlated with
increased fecal MPO and with increased neopterin. In addition, the tendency for stunted chil-
dren to experience “catch-up growth” was clearly shown in the association of stunting at study
start (HAZss) with better subsequent growth as shown in Fig 6. The host attempt to “catch up”
when challenged by growth impairing conditions has also been shown in intestinal cells, where
“catch-up” intestinal cell kinase (ICK) is stimulated both in vitro and in vivo by even brief pro-
tein deprivation [49].
Intestinal inflammation can also further disrupt barrier function in a vicious cycle. Several
fecal biomarkers have emerged as helpful tools in the assessment of intestinal inflammation or
immune stimulation. As noted in our methods section, and having studied others (lactoferrin,
calprotectin and lipocalin-2with MPO) [33], we selectedMPO and neopterin. The marker of
intestinal epithelial cell repair, Reg-1B correlates with Lcn-2 [50], as it does with the marker of
more severe barrier disruption, A1AT [51] in these fecal samples.
Although a poorly sensitive assay of structural intestinal barrier disruption, the serumpro-
tein that is inherently resistant to digestive degradation, A1AT has offered another biomarker
that has shown correlations with epithelial destruction in previous studies [52]. Like lactulose
absorption in the L/M test, these markers of barrier disruption could well represent key initiat-
ing or, with A1AT, later events in the development and progression of EE. A recent report by
Brown et al [20] suggests that dietary deficiencies alone are insufficient to trigger inflammatory
or villus architectural disruption without certainmicrobial components.
Plasma citrulline, an amino acid predominantly synthesized in proximal intestinal epithelial
cells and only minimally present in the diet, appears to reflect healthy epithelium that is strik-
ingly reduced in short bowel syndrome, AIDS enteropathy and other villus atrophy syndromes
[53]. Its association with better subsequent growth, albeit with initial stunting suggests that it
may play a key role in ‘catch-up’ growth, which, when possible is definitely greater in stunted
children.
The acute phase protein, SAA (serum amyloid A protein) can be triggered by selected
microbiota (segmented filamentous bacteria, SFB) [54] and has been shown to induce epige-
netic alterations via JMJD3 that removes the methylation from the H3K27 repressor of the pro-
motors of IL-23, G-CSF and TREM-1, and thus drives proinflammatory cytokine production
[55, 56]. Hence, its association with fecal MPO, plasma hsCRP, sCD-14, LBP, kynurenine and
K/T ratios (albeit with better HAZ at study start, perhaps reflectingmore robust host
responses, while also predicting poorer subsequent growth as shown in Fig 2F, and negatively
with tryptophan suggest its potential role as not only a biomarker, but a potential pathway
involved in the development of environmental enteropathy.
REG1B, the product of regenerating gene1 and marker of intestinal cell damage has been
previously associated with growth failure in children in Bangladesh [50]. It has also been
recently shown to cluster with sCD14, A1AT, MPO, calprotectin, and neopterin in these chil-
dren linking environmental enteropathy (EE) with oral vaccine failure [57].
Soluble CD14 is secreted by monocytes and macrophages in response to LPS, and hence
joins LBP in reflecting systemic responses to LPS translocation [58]. The marker of enterocyte
death, intestinal fatty acid binding protein (I-FABP) [59] joins biomarkers of structural barrier
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disruption, including L/M and %L as well as A1AT and Reg1 as an indicator of monocyte
responses to LPS bioactivity, sCD14 has also been associated with increased IL6, CRP, SAA, D-
dimer and increasedmortality in HIV-infected individuals [60], as well as directly measured
LPS and I-FABP, all presumably reflecting an enteropathy with increasedmicrobial (or micro-
bial product) translocation [61]. The association of zonulin with LBP, IgG anti-LPS and anti-
FliC, low tryptophan and malnutrition (lower SSWAZ for all children and, if greater than 12
months old, also SS HAZ) is consistent with the involvement of this tight junctionmodulator
early in development of EE [62], while the reduced zonulin with increasedA1AT or neopterin
may reflect compensatory zonulin pathway down-regulation secondary to epithelial disrup-
tion. Interestingly in the Principle Components analyses (Fig 5), reduced zonulin with
increasedA1AT and Reg1 associated with both increasedMPO and neopterin.
To our knowledge, this is the first evaluation of urinary claudin-15 as a biomarker for
healthy gut function. Previous studies by Thuijls and colleagues usedWestern blotting to mea-
sure significant elevations of urinary claudin-3 in patients with active IBD versus those in
remission or healthy controls [63]. Here, we successfully used ELISA to quantify urinary clau-
din-15 and uncovered inverse correlations with urinary L/M, and fecal A1AT, lipocalin-2, and
Reg-1. Claudin-15 is highly expressed throughout the intestine [64] in an age-dependent man-
ner [65]. Interestingly, lactating rats upregulate small intestinal Cld-15 expression in associa-
tion with villous hypertrophy and enhanced calcium absorption [66], whereas Cld-15 ko
display megaintestine and sodium deficiency and glucosemalabsorption in the small intestine
[67]. Taken together, this suggests that increased urinaryCld-15, like urinarymannitol, is a
positive biomarker of gut health.
Potential pathways involved may thus include enteric pathogens (especially bacteria and
protozoa) that compound dietary insufficiencies to disrupt intestinal mucus and epithelial bar-
rier function, thereby enabling translocation of microbial LPS that triggers both local intestinal
as well as systemic inflammatory signaling. Intestinal inflammation can also further disrupt
barrier function in a vicious cycle. Both pathogen exposure and inadequate diet are products of
poverty, with its concomitant inadequate water, sanitation and food. Our principle compo-
nents analyses of biomarkers reveal that correlated groups of biomarkers that can be said to
reflect barrier disruption have significant correlations with subsequent growth (as does initial
HAZ) as well as with fecal and systemic biomarkers and selectedmetabolites.
Our findings in this report thus support the hypothesis that the systemic effects of potential
intestinal barrier disruption and local inflammation on growth are likely occurring through
effects of systemic inflammation that have indirect effects through impairing the hepatic syn-
thesis of such key growth mediators as IGFBP-3 and IGF-1, as suggested by DeBoer et al [in
press]. However, additional key pathways may also include effects via citrulline or via trypto-
phan metabolism. These key metabolites may become less available for intestinal injury repair
because of increased demands or because of altered host or microbial metabolism or signaling.
For example, the activation of indoleamine 2,3-dioxygenase-1 (IDO-1) by microbial transloca-
tion or LPS has been shown to be triggered in dendritic cells and monocytes to skew CD4+ T-
cell differentiation away from T-helper (Th17) to regulatory T cells (Tregs) [68]. We thus find
that lower plasma tryptophan levels not surprisingly associate with biomarkers of barrier dis-
ruption and intestinal and systemic inflammation, including higher L/M, zonulin, fecal MPO
and lactoferrin, and higher hsCRP, SAA, sCD14, kynurenine and K/T ratios; while lower tryp-
tophan is associated with lower citrulline. Indeed, in metabonomic studies of all metabolites in
the urines of these children, we have recently found that tryptophan is likely depleted via both
gut microbial metabolism (through the indole pathway to measureable increases in urinary
3-indole sulfate) as well as via the endogenous IDO/kynurenine pathway (as indicated by the
increased nicotinic acid, N-methyl nicotinamide and 2-PY metabolites seen in the urine of
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these undernourished children, by WAZ or HAZ) [69]. In summary, we find that MPO,
A1AT, LPS, L/M, I-FABP, and SAA, as well as MPO+ neopterin, and combinations of L/M and
%L associate with impaired subsequent growth, with the reverse of these as well as citrulline (in
girls) and tryptophan (in boys) offering potential predictors of better growth.
We conclude that fecal MPO and A1AT, and L/M, plasma LPS-neutralizing activity,
I-FABP, SAA, hsCRP, citrulline and tryptophan provide promising biomarkers that associate
with intestinal barrier disruption, local and systemic inflammation and potential catch-up
growth involved in “environmental enteropathy.” These fecal, urinary and systemic biomarkers
can prove useful in several ways. First, by improving our understanding of the pathogenesis
and its long-term physical and cognitive consequences, they can elucidate its early recognition
as well as innovative approaches to ameliorate its potentially devastating impact. Furthermore,
they can provide targeted assessment tools with which to evaluate the effectiveness of novel
interventions and improved approaches to controlling the potential lasting stunting and devel-
opmental consequences of frequent or repeated enteric infections in young children living in
impoverished settings. Thus these key biomarkers can help complete the cycle of recognition,
understanding, intervening and finally documenting causality of EE and its likely long-term
consequences for healthy child development in areas of greatest need.
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